Mindset Pharma

0:21:33

How Mindset Pharma Dealt Partnership With Otsuka - TDR Exclusive

0:12:23

Mindset Pharma: A Leadership Position in Psychedelics

0:13:53

The Future of Psychedelic Medicines with Mindset Pharma

0:05:10

Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery

0:04:30

Mindset Pharma enters exclusive reseller deal with PharmAla for its pharmaceutical-grade psilocybin

0:06:14

Management of Mindset Pharma Educates us on the Basics of Psychedelic Patents!!!

0:10:53

Mindset Pharma positioned for strong future

0:00:30

Mindset Pharma Inc. (MSET:CSE)

0:06:59

Mindset Pharma and PharmAla partnership makes first medical grade psilocybin sale in Australia

0:00:58

$PSYC Highlights Featuring Mindset Pharma

0:17:55

Mindset Pharma: Shareholder Value in Psychedelics

0:04:13

Mindset Pharma shares positive preclinical results on its two sets of psychedelic drug families

0:03:57

Mindset Pharma (MSET): The Next Generation of Intellectual Property in the Psychedelics

0:04:50

Mindset Pharma and InterVivo release first joint data set focused on psilocybin

0:14:08

Mindset Pharma: Leaders in Next-Gen Psychedelics

0:01:01

Greenshoe Minute Commercial - Mindset Pharma Inc. (MSET:CSE)

0:05:02

Mindset Pharma says US Patent and Trademark Office allowance underscores the strength of its IP

0:11:45

Mindset Pharma (MSET) Announces Psilocybin Breakthrough Drug

0:07:05

Psychedelic Insights: Mindset Pharma - James Lanthier CEO

0:03:50

Mindset Pharma receives Notice of Allowance for psilocin derivatives patent application

0:04:58

Mindset Pharma identifies additional drug candidates from 'Family 3' psilocybin compounds

0:14:02

Mindset Pharma: The Real Opportunities in the Psychedelic Market

0:05:54

Mindset Pharma chooses pair of psychedelic drug candidates to move Family 2 program forward

0:06:22

Mindset Pharma CEO says the firm's recent efforts in the psychedelic space are delivering